Cargando…
S9.3d Antivirulence drug discovery to disarm Candida albicans with metabolites from myxobacteria.
S9.3 DRUG RESISTANCE IN EMERGING PATHOGENIC FUNGI, SEPTEMBER 23, 2022, 4:45 PM - 6:15 PM: Candida albicans is an opportunistic fungal pathogen. While nearly 40%-60% of humans are colonized harmlessly by C. albicans, prolonged use of antibiotics or an immune-compromised status can lead to mucosal or...
Autores principales: | Vij, Raghav, Tröger, Sophie, Walt, Christine, Haeckl, F.P. Jake, Müller, Rolf, Kniemeyer, Olaf, Brakhage, Axel, Hube, Bernhard, Brunke, Sascha |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9511645/ http://dx.doi.org/10.1093/mmy/myac072.S9.3d |
Ejemplares similares
-
Uncharted territories in the discovery of antifungal and antivirulence natural products from bacteria
por: Vij, Raghav, et al.
Publicado: (2021) -
Antivirulence and avirulence genes in human pathogenic fungi
por: Siscar-Lewin, Sofía, et al.
Publicado: (2019) -
The arsenal of pathogens and antivirulence therapeutic strategies for disarming them
por: Brannon, John R, et al.
Publicado: (2016) -
P003 Synthetic antifungal peptide mimic kills Candida albicans by targeting protein glycosylation and synergistically prevents infection
por: Schaefer, Sebastian, et al.
Publicado: (2022) -
Two unlike cousins: Candida albicans and C. glabrata infection strategies
por: Brunke, Sascha, et al.
Publicado: (2013)